{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=59", "query": { "intervention": "combined therapy treatment", "page": 59 }, "page_size": 10 }, "pagination": { "page": 59, "page_size": 10, "total_count": 12534, "total_pages": 1254, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=60&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=58&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T07:34:33.619Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05249114", "title": "Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Lu-177", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-12-28", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-24T07:34:33.619Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05249114" }, { "nct_id": "NCT03330106", "title": "A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Neoplasm" ], "interventions": [ { "name": "Pevonedistat", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2017-11-15", "completion_date": "2021-06-21", "has_results": true, "last_update_posted_date": "2023-03-28", "last_synced_at": "2026-10-24T07:34:33.619Z", "location_count": 8, "location_summary": "Santa Monica, California • Tampa, Florida • Detroit, Michigan + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03330106" }, { "nct_id": "NCT04174352", "title": "FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "ERα+ Breast Cancer", "ESR1 Gene Mutation" ], "interventions": [ { "name": "Tamoxifen", "type": "DRUG" }, { "name": "FES PET/CT", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 12, "start_date": "2020-10-20", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-24T07:34:33.619Z", "location_count": 2, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04174352" }, { "nct_id": "NCT04663347", "title": "Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone", "type": "DRUG" }, { "name": "Rituximab and Lenalidomide", "type": "DRUG" }, { "name": "rituximab and bendamustine", "type": "DRUG" }, { "name": "rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin", "type": "DRUG" }, { "name": "gemcitabine and oxaliplatin", "type": "DRUG" }, { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "rituximab, ifosfamide, carboplatin, and etoposide phosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 543, "start_date": "2020-11-03", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-24T07:34:33.619Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04663347" }, { "nct_id": "NCT04408638", "title": "A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Glofitamab", "type": "DRUG" }, { "name": "Rituxumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2021-02-23", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-24T07:34:33.619Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Fresno, California • Jacksonville, Florida + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04408638" }, { "nct_id": "NCT07750158", "title": "Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Zanzalintinib", "type": "DRUG" }, { "name": "Pembrolizumab (+) Berahyaluronidase alfa", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2026-08-25", "completion_date": "2030-04-05", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-24T07:34:33.619Z", "location_count": 13, "location_summary": "Council Bluffs, Iowa • Grand Island, Nebraska • Omaha, Nebraska + 7 more", "locations": [ { "city": "Council Bluffs", "state": "Iowa" }, { "city": "Grand Island", "state": "Nebraska" }, { "city": "Grand Island", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT07750158" }, { "nct_id": "NCT06376032", "title": "EndeavorOTC® Research Study in College Students", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Attention", "Cognition", "University Students" ], "interventions": [ { "name": "EndeavorOTC®", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Akili Interactive Labs, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2024-01-10", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-06-27", "last_synced_at": "2026-10-24T07:34:33.619Z", "location_count": 2, "location_summary": "Cheektowaga, New York • Putney, Vermont", "locations": [ { "city": "Cheektowaga", "state": "New York" }, { "city": "Putney", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT06376032" }, { "nct_id": "NCT03144687", "title": "A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MPN (Myeloproliferative Neoplasms)" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2018-01-26", "completion_date": "2021-06-01", "has_results": true, "last_update_posted_date": "2022-06-16", "last_synced_at": "2026-10-24T07:34:33.619Z", "location_count": 19, "location_summary": "Tempe, Arizona • Orange, California • Aurora, Colorado + 16 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03144687" }, { "nct_id": "NCT02959021", "title": "Partnership Optimizes Weight Management in Primary Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "weight loss intervention - self directed", "type": "BEHAVIORAL" }, { "name": "weight loss intervention - peer coach", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 375, "start_date": "2017-01", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-10-24T07:34:33.619Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02959021" }, { "nct_id": "NCT02562521", "title": "A Smoking Cessation Intervention for Yale Dining Employees", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Smoking Cessation" ], "interventions": [ { "name": "Contingency management", "type": "BEHAVIORAL" }, { "name": "Nicotine replacement therapy", "type": "DRUG" }, { "name": "Varenicline", "type": "DRUG" }, { "name": "Additional behavioral support", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2015-09", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-04-09", "last_synced_at": "2026-10-24T07:34:33.619Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02562521" } ] }